Finance

Lists
ANRO:NYSE
Alto Neuroscience Inc
24,37 USD
+1,41%
(+0,34) 1D
24,37 USD
0,00% (0,00)
After hours
Closed: 9-окт., 16:00:04 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ANRO...
Open
24,00 USD
High
25,11 USD
Low
23,81 USD
Mkt. cap
956,33 млн
Avg. vol.
566,23 миң
Volume
649,43 миң
52-wk high
37,48 USD
52-wk low
5,22 USD
EPS
-2,44 USD
Shares outstanding
39,24 млн
No. of employees
68
Open
24,00 USD
High
25,11 USD
Low
23,81 USD
Mkt. cap
956,33 млн
Avg. vol.
566,23 миң
Volume
649,43 миң
52-wk high
37,48 USD
52-wk low
5,22 USD
EPS
-2,44 USD
Shares outstanding
39,24 млн
No. of employees
68
News stories
From web sources and news partners
About Alto Neuroscience Inc
CEO-
Employees68
Founded2019
Headquarters-
SectorPharmaceutical industry
Websitealtoneuroscience.com
Analyst ratings
Based on 5 analysts giving stock ratings to ANRO in the past 3 months
Strong buy
Buy
5
Hold
0
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ANRO in the last 3 months.
Highest
Current 24,37 USD
55,00 USD (+125,69%)
Average
44,00 USD (+80,55%)
Lowest
37,00 USD (+51,83%)
Analyst
Recommendation
Action
Price target
Projected
Date
Myles Minter
William Blair
Buy
Reiterated
-
-
10/02/2026
Patrick Trucchio
H.C. Wainwright
Buy
Maintained
55,00 USD
+125,7%
09/21/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
08/14/2026
Andrew Tsai
Jefferies
Buy
Maintained
40,00 USD
+64,1%
08/13/2026
Thomas Shrader
BTIG
Buy
Reiterated
37,00 USD
+51,8%
08/13/2026
Justin Walsh
JonesTrading
Buy
Reiterated
44,00 USD
+80,5%
06/26/2026
Brian Skorney
Robert W. Baird
Buy
Maintained
36,00 USD
+47,7%
05/18/2026
Laura Chico
Wedbush
Hold
Maintained
24,00 USD
-1,5%
05/14/2026
Ritu Baral
TD Cowen
Buy
Maintained
-
-
05/13/2026
Keay Nakae
Chardan Capital
Buy
Maintained
30,00 USD
+23,1%
04/21/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
33,00 USD
+35,4%
04/02/2026
Last report
2026-ж., 12-авг.
Fiscal period
Q2 2026
-0,65 USD / -0,77 USD
+15,95%beat
Revenue / Est. (USD)
- / 0,00
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
10,52 млн
12,00 млн
20,29 млн
22,11 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
4,43 млн
5,06 млн
6,84 млн
7,02 млн
Operating expense
14,95 млн
17,06 млн
27,14 млн
29,13 млн
Total operating expenses
14,95 млн
17,06 млн
27,14 млн
29,13 млн
Operating income
-14,95 млн
-17,06 млн
-27,14 млн
-29,13 млн
Other non operating income
-112,00 миң
-113,00 миң
-115,00 миң
-130,00 миң
EBT including unusual items
-14,18 млн
-16,18 млн
-26,24 млн
-27,64 млн
EBT excluding unusual items
-14,18 млн
-16,18 млн
-26,24 млн
-27,64 млн
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-14,18 млн
-16,18 млн
-26,24 млн
-27,64 млн
Net profit margin
-
-
-
-
Earnings per share
-0,52
-0,45
-0,80
-0,65
Interest and investment income
1,53 млн
1,56 млн
1,56 млн
2,11 млн
Interest expense
-650,00 миң
-575,00 миң
-545,00 миң
-491,00 миң
Net interest expenses
882,00 миң
986,00 миң
1,02 млн
1,62 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
-14,79 млн
-16,90 млн
-26,95 млн
-28,94 млн
Gain or loss from assets sale
114,00 миң
-
9,00 миң
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google колдонмолору